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0.50-NUR; 0.42-PH) and low or insigniﬁcant for Pain (0.32-
FAM; 0.40-NUR; 0.18-PH) and Anxiety/Depression (0.26-FAM;
0.28-NUR; 0.14-PH). The variables associated to the difference
between the VAS score of patient and carriers were studied using
lineal regression. Mean (S.D) PCS and MCS of caregivers were
48.4 (13.8) and 48.0 (11.3). Multiple regression analysis showed
that higher ZS and older patient age were associated to lower
PCS of the caregiver (R2 = 0.15; p < 0.001) and that higher ZS
and lower FSS of the caregiver, and lower MCS of the patient
were associated to lower MCS of the caregiver (R2 = 0.29; p <
0.001). Lower FSS, PCS and MCS of the caregiver and higher
age and lower PCS and MCS of the patient were associated to
higher score on ZS of caregivers (R2 = 0.49; p < 0.001). CON-
CLUSIONS: Agreement between patients and carriers was mod-
erate for “objective” dimensions of HRQOL and low for
“subjective” ones. HRQoL of FAM is slightly worse than that
of the general population. The burden of FAM depends on per-
ceived social support, patient’s age and health status of carrier
and patient.
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VARIABILITY IN QOL QUESTIONNAIRES AND THE
HANDLING OF MISSING DATA IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER TREATED WITH
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OBJECTIVES: To review quality of life (QoL) questionnaire use
and methods for handling missing data in published chemother-
apy studies [2000–2005 (Jan)] of non-small cell lung cancer
(NSCLC). METHODS: We conducted a detailed search of the
published literature on quality of life, NSCLC, and chemother-
apy, excluding studies with limited total sample size (<50).
Thirty-ﬁve studies covering 10 QoL questionnaires and 17
chemotherapy drugs were reviewed. RESULTS: Most studies
were conducted in Europe (primarily Italy and the U.K.), and the
average sample size was 137 patients per treatment arm (range:
16, 406). QoL questionnaires were typically self-administered at
baseline and every 3 weeks thereafter until disease progression
(roughly 2 years duration). The EORTC QLQ-C30 and EORTC
QLQ-LC13 (QLQ-LC13) questionnaires were most often used
in Europe (15 of 24 European studies); however, the FACT-L
questionnaire was commonly used in the U.S. (7 of 13 U.S.
studies). The EORTC QLQ-C30/QLQ-LC13 combination
detected signiﬁcant differences for QoL outcomes in 14 of 15
studies which reported EORTC domain scores, while the FACT-
L detected differences in 3 of 7 studies. Both questionnaires
contain similar domains, but the EORTC QLQ-C30/QLQ-LC13
includes more items on chemotherapy symptoms and FACT-L
includes items on patients’ attitude towards their cancer. Several
studies examined potential non-random bias due to missing data
resulting from death or disease progression. One study detected
conﬂicting results when including (versus excluding) missing
data from their analyses. Another study observed different QoL
results when comparing cycle-to-cycle data at similar time points
rather than study completion data using the last observation
carried forward. CONCLUSIONS: Although EORTC QLQ-
C30/QLQ-LC13 and FACT-L are both widely used, are similar
in content, and can detect differences in NSCLC patients, they
are used preferentially in Europe and the U.S, respectively. Inap-
propriate assumptions concerning the randomness of missing
data can result in biased estimates of QoL.
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THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS
BASED ON THE A SYNTHESIS OF THE RESULTS OF 15
RANDOMISED CONTROLLED TRIALS
Hawkins N, Sculpher M
University of York,York, UK
OBJECTIVES: To inform coverage decisions regarding drug-
eluting coronary stents by assessing their cost-effectiveness for
particular high-risk patient subgroups. METHODS: The analy-
sis compared the cost-effectiveness of the two drug eluting stents
(DES) available in the UK (Cypher and Taxus) and bare-metal
stents (BMS). A review was undertaken of randomised trials
including one or both of the DES. Individual patient data were
available for some of these trials. The model parameters
extracted from the trials were further revascularisation rates,
undertaken for clinical reasons, either percutaneous interven-
tions or bypass surgery, during follow-up. Three subgroups were
considered on the basis of their higher baseline risk of repeat
revascularisation: small vessels, long lesions and diabetics; a
fourth subgroup without these risk factors was also considered.
The evidence synthesis was implemented as a Bayesian hierar-
chical logistic model. A probabilistic decision model was devel-
oped. RESULTS: Evidence from 15 trials was incorporated into
the synthesis, 5 of which supplied individual patient data. The
probability of repeat percutaneous interventions was lowest with
Cypher and highest with BMS. Both DES had lower probabili-
ties of subsequent bypass surgery than BMS, and the probability
for Taxus was slightly lower than for Cypher. Cost-effectiveness
results were sensitive to the stent prices. At current UK prices
(£908 BMS, £1300 Taxus, £1341 Cypher), Taxus is dominated
by Cypher in diabetic patients and subject to extended domi-
nance in all other subgroups. Cypher has an incremental cost per
QALY gained, compared to BMS, of £13,759, £23,086, £13,740
in patients with small vessels, long lesions and diabetes, respec-
tively. In patients with no risk factors, this increases to £35,865.
CONCLUSIONS: Given existing list prices, Cypher is likely to
be considered more cost-effective than BMS and Taxus in
patients at high baseline risk of further revascularization. This
conclusion may change following any changes in the relative
stent prices.
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PREDICTING THE COST-EFFECTIVENESS OF THE ABT-578
COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE
NOVO NATIVE CORONARY ARTERY LESIONS
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OBJECTIVES: Endeavor combines the Driver stent, the drug
ABT-578 and a PC polymer into a new drug-eluting coronary
artery stent (DES) system. As results from long-term trials of
Endeavor are not yet available, economic modeling techniques
must be employed to evaluate the cost-effectiveness of this new
treatment option. The study undertook the ﬁrst assessment of
the cost-effectiveness of Endeavor DES, compared to the Driver
bare-metal stent (BMS), in the treatment of de novo lesions in
native coronary arteries. METHODS: A Markov model was
developed simulating the results of the ENDEAVOR II trial at
nine months follow-up, and extrapolating to ﬁve years using the
BENESTENT I trial. No difference was assumed between the
outcomes with the two stents after the ﬁrst year. The events
modeled were target vessel revascularisations, AMIs, cere-
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brovascular accidents and death. The expected costs were cal-
culated for 2005 from the perspective of the UK NHS. Each
event was associated with a transient decrement in health-related
utility due to recurrent symptoms while waiting for a repeat
intervention and to pain and distress of events or further inter-
ventions, relative to a baseline asymptomatic coronary heart
disease value based on the ARTS and SoS trials. A probabilistic
sensitivity analysis was undertaken. RESULTS: Although the
price premium of Endeavor is above £500, the total cost of
Endeavor treatment was only slightly higher at ﬁve years than
Driver (£6094 vs. £6058) due mainly to the reduced need for
revascularisations in the ﬁrst year. Endeavor was also associated
with QALY gains (0.0053 per patient), and therefore had an
incremental cost-effectiveness ratio of ~£6700/QALY. The prob-
ability of Endeavor being cost-effective at a threshold of
£30,000/QALY was 58%. CONCLUSIONS: This exploratory
analysis shows the Endeavor DES to be cost-effective. Results of
long-term trials are awaited to conﬁrm model predictions.
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HEALTH ECONOMIC EVALUATION OF BIVALIRUDIN IN THE
MANAGEMENT OF PATIENTS UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION IN BELGIUM
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OBJECTIVE: To determine the cost-effectiveness (CE) from the
Belgian societal perspective of anticoagulation with bivalirudin
vs. heparin + glycoprotein inhibitors (GPIIb/IIIa) in patients
undergoing percutaneous coronary intervention (PCI).
METHODS: Efﬁcacy data were taken from REPLACE-2, EPIS-
TENT and ESPRIT trials which documented probabilities of PCI
outcomes: death, myocardial infarction, urgent revasculariza-
tion, and major/minor bleedings according to TIMI deﬁnition.
Costs data were drawn from Belgian literature except for drug
costs which were valued using REPLACE-2 actual dosages and
ofﬁcial Belgian tariffs. We considered unfractionated (UFH) and
low-molecular weight (LMWH) heparins. Abciximab was the
only GPIIb/IIIa considered as it is the only one indicated for PCI
in Belgium. A 30-day time frame analytical model was developed
from an original model by The Swedish Institute for Health Eco-
nomics (IHE), to estimate the incremental costs per life year
gained (LYG). Costs and LYG were discounted at 3.0% per
annum. In the base case analysis, GPIIb/IIIa was given in 27.5%
of the patients receiving heparin (consensus estimate between the
Belgian Working Group in Interventional Cardiology and expert
opinions). RESULTS: Giving bivalirudin to the average patient
undergoing PCI in Belgium resulted in extra 0.0794LYG and
€90.1 vs. UFH (incremental cost-effectiveness ratio (iCER) =
€1134.8/LYG). LMWH was dominated. A threshold analysis,
varying from 0% to 100% the percentage of patients in the
heparin branches who receive additional GPIIb/IIIa, revealed
that when this percentage is above 34%, bivalirudin dominates
both heparin strategies. When no patient at all was given addi-
tional GPIIb/IIIa, the iCER vs. UFH was €3933.3/LYG. Other
variables were much less sensitive. CONCLUSION: Our analy-
sis suggests that the use of bivalirudin during PCI is a cost-effec-
tive alternative to the current approach of heparin + GP IIb/IIIa
in the Belgian health care setting. The percentage of patients
given GPIIb/IIIa with heparin is the key factor driving the iCER
of bivalirudin.
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OBJECTIVES: Primary bare metal stenting and abciximab infu-
sion are currently considered the best available reperfusion strat-
egy for acute ST-segment elevation myocardial infarction
(STEMI). Sirolimus eluting stents (SES), compared to bare metal
stent (BMS), greatly reduce the incidence of binary restenosis and
target vessel revascularisation (TVR), but their use on a routine
basis results in a signiﬁcant increase in medical costs. With
current European list prices, the use of tiroﬁban (TIRO) instead
of abciximab (AB) would save enough money to absorb the dif-
ference in cost between SES and BMS. The STRATEGY study
examined the safety and efﬁcacy of tiroﬁban and SES vs. AB and
BMS in STEMI patients. To evaluate the short- and medium-term
economic impact of the STRATEGY combination, namely TIRO
+ SES versus current golden standard of treatment, AB + BMS.
METHODS: A medium-term (one year or 8 months) decision
analytic model was developed to conduct a cost-effectiveness
analysis using a cost per survival. The perspective of the model
was that of Italy. Clinical outcomes (mortality, myocardial
infarction (MI), revascularization (Revasc) and major cardiac
events (MACE) were based on the ﬁnal results of the STRAT-
EGY study. Costs were obtained from Italian sources for device
and hospitalization data (€2004). Total expected costs and out-
comes for TIRO + SES versus AB + BMS were compared. The
robustness of the results was tested in a sensitivity analysis.
RESULTS: Clinical outcomes were lower for TIRO + SES when
compared to AB + BMS for mortality (0.079 vs. 0.089), MI
(0.068 vs. 0.089), Revasc (0.067 vs. 0.197) and MACE (0.214
vs. 0.377). The average overall cost of TIRO + DES (€23,674)
was less expensive than that of AB + BMS (€24,274) with an
incremental difference of €600. One-way sensitivity analysis
indicated the model was sensitive to the unit cost of AB with a
threshold value of €338. CONCLUSIONS: TIRO + SES resulted
to be the dominant strategy.
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TREATMENT PATTERNS AMONG POSTMENOPAUSAL
OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY
BISPHOSPHONATE THERAPY
Huybrechts KF1, Ishak KJ2, Proskorovsky I2, Caro JJ1, Levinton C1
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OBJECTIVE: To compare treatment patterns, speciﬁcally per-
sistence and compliance, among postmenopausal osteoporotic
women treated with daily or weekly bisphosphonates.
METHODS: Data were obtained from a US managed care data-
base. The study cohort included women with an osteoporosis
diagnosis (ICD-9 code 733.0) followed by a prescription for
alendronate 10mg (daily) or 70mg (weekly), risedronate 5mg
